Implementation of Eplet Mismatch Analysis in Pediatric Kidney Transplantation
Implementation of Eplet Mismatch Analysis in Pediatric Kidney Transplantation
批准号:
10739126
负责人:
Olga Charnaya
金额:
$17.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2027-05-31
关键词:
AddressAgeAlgorithmsAllograftingAmino Acid SequenceAntibodiesAntibody FormationAntibody ResponseBiometryCharacteristicsChildChildhoodChronicClinicalClinical DataClinical ResearchCompetenceComputer ModelsComputer softwareConduct Clinical TrialsDataData AnalysesDevelopmentDialysis procedureDoctor of PhilosophyElementsEnd stage renal failureEnsureEpitopesEquityEtiologyFailureGenotypeGeographyGoalsGraft SurvivalHLA AntigensHistocompatibility TestingImmune responseImmune systemImmunogeneticsImmunologicsIncidenceInjuryInterventionKidneyKidney TransplantationLearningMediatingModalityModelingMolecularMorbidity - disease rateNatureOrganOrgan DonorOrgan ProcurementsOutcomeOutputPoliciesPublic Health SchoolsRaceResearchResearch DesignResearch MethodologyResearch PersonnelResolutionRetrospective StudiesRiskRisk FactorsRisk ReductionSiteSystemTechniquesTechnologyTestingTimeTrainingTransplant RecipientsTransplantationTransplantation ImmunologyUncertaintyUnited StatesWait TimeWaiting ListsWorkaccess disparitiesantibody detectionburden of illnesscareerclinical developmentclinical practicecohortdata managementdesigndissemination scienceeffective therapygeographic disparitygraft failurehazardhigh riskimmunogenicityimplementation scienceimprovedimproved outcomenovelorgan allocationorgan procurement transplantation networkracial disparityskillstooltransplant centers
中文摘要
与透析相比,肾移植(KT)提供了显著的生存和发病率优势,使其成为最佳的治疗方案
英文摘要
Kidney transplant (KT) offers a significant survival and morbidity benefit over dialysis, making it the
preferred treatment modality for end-stage kidney disease. While late allograft failure has a multifactorial
etiology, one of the largest contributors is the development of donor specific HLA antibodies (dnDSA), leading
to allograft loss at a median 3-5 years post detection of antibodies. Donor specific HLA antibodies develop
against short amino acid sequences within the HLA antigen. Each HLA antigen has multiple epitopes that can
interact with the recipient immune system, and antibody-verified epitopes are termed “eplets”. Mismatched
epitopes can be identified and enumerated using various molecular mismatch software packages. However,
not all epitopes are equally likely to induce an antibody response in the recipient, as specific “high-risk” eplet
mismatches were found to be disproportionally associated with dnDSA formation. Avoidance of high-risk
mismatches between donor and recipient at the time of organ allocation is one way to improve long-term
allograft survival because it would reduce the number of potential dnDSA targets.
Variable immunogenicity is an accepted concept however details about which mismatches are high risk
has not been well established. I propose to establish a multi-site pediatric kidney transplant (KT) cohort with full
HLA genotyping on recipients and donors to perform such an analysis. This will inform the development of an
adaptive allocation model, that can better account for the entangled and dynamic nature of allocation systems.
The Organ Procurement and Transplant Network (OPTN) has mandated the development of a new allocation
model, to develop a composite allocation scoring system that can account for dynamic changes in multiple
recipient and donor characteristics. There is insufficient data to inform such a model on how to handle HLA
mismatch on an epitope-level. My work with the multi-site cohort will inform how to best inform incorporate
molecular mismatch analysis and high-resolution tissue typing data into an adaptive allocation model.
My career goal is to become an independent clinical researcher focused on improving outcomes for KT
recipients by studying the adaptive and humoral immune response to the allograft and conducting clinical trials
to test interventions to reduce the burden of disease. By completion of the proposed research and didactic
training at the Johns Hopkins School of Public Health, I will obtain a PhD in Clinical Research Methodology
and develop a unique skillset that will allow me to establish an independent research career in transplant
immunology. Specifically, I will gain expertise in multi-site study design and execution, large data management
and analysis, advanced computational modeling, and application of immunogenetics to clinical practice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: